MedPath

A Study of Neurofeedback for the Treatment of Parkinson's Disease

Not Applicable
Conditions
Parkinson Disease
Interventions
Other: Training with Neurofeedback
Other: The other Training with Neurofeedback
Registration Number
NCT03837548
Lead Sponsor
Osaka University
Brief Summary

This study aims to reveal relationship between brain activities and the symptoms of Parkinson disease when a neurofeedback training was applied for them.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Subjects with age more than 20
  • Subjects obtained the consent
  • Subjects with Parkinson disease and healthy subjects
Exclusion Criteria
  • The subjects who can not conduct the tasks
  • Subjects with severe illness
  • Subjects whom the experimenter think as in appropriate
  • Subjects with implantable devices such as pacemaker

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Training with NeurofeedbackTraining with Neurofeedback-
The other Training with NeurofeedbackThe other Training with Neurofeedback-
Primary Outcome Measures
NameTimeMethod
Alteration of Brain ActivitiesAt the time Immediately following the training

measured by magnetoencephalography

Secondary Outcome Measures
NameTimeMethod
The raw score change from baseline in the Movement disorder society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part Ⅲ scoresAt the time Immediately following the training

MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The scales are now titled; (Part I) nonmotor experiences of daily living (13 items), (Part II) motor experiences of daily living (13 items), (Part III) motor examination (18 items), and (Part IV) motor complications (six items). Each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.

The total score is the sum of the subscale scores for Part III and ranges from 0 (no disability) to 132 (total dependence).

Trial Locations

Locations (1)

Osaka University

🇯🇵

Suita-City, Osaka-fu, Japan

© Copyright 2025. All Rights Reserved by MedPath